Status:

TERMINATED

Antihypertensive Efficacy of Fixed Combination Drug

Lead Sponsor:

Meir Medical Center

Collaborating Sponsors:

Dexcel Pharma Technologies Ltd.

Conditions:

Hypertension

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

Treatment and control of hypertension is still insufficient. About 50% of the patients remain uncontrolled. Lack of compliance with discontinuation of drug treatment is an important reason for not ach...

Detailed Description

This is a single centre observational uncontrolled prospective study, Hypertensive patients that are either treatment naïve or uncontrolled on current therapy \[one or two drugs\] and meet all inclusi...

Eligibility Criteria

Inclusion

  • Essential hypertension at visit 1 defined as office blood pressure \<140/90 mmHg and a 24 h ABPM \>130/80 mmHg with a day time blood pressure (extracted from the 24h ABPM) \>135/85 mmHg
  • Male and female
  • Age 18-80
  • Every patient that in the medical opinion of the treating physician is eligible for Vasodip Combo 20 treatment.
  • Willing to sign an informed consent

Exclusion

  • Use of more than 2 anti hypertensive medication at visit 1 (fixed combination is considered as two drugs)
  • Mean 24 h ABPM values of more than 180/100 mmHg
  • Pregnant women
  • Women with potential age of pregnancy.
  • Suspected secondary hypertension (investigator decision)
  • Uncontrolled Diabetes Mellitus(investigator decision)
  • Any of the following in the last six months: Myocardial Infarction, Stroke, Coronary by-pass surgery, Percutaneous coronariography with balloon dilation and/or stent insertion
  • Congestive Heart Failure requiring pharmacological treatment
  • Renal Failure, defined as serum creatinine equal or great than 1.5 mg% \[confirmed twice\] or hyperkalemia defined as serum potassium equal or great that 5 meq/l \[confirmed twice\]
  • Malignancy that required Chemotherapy in the last 3 years.
  • Any medical or none medical condition that in the eyes of the investigator will not allow the patient to complete the study.

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2012

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT01211314

Start Date

January 1 2011

End Date

April 1 2012

Last Update

June 28 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Clalit Health Services

Herzliya, Hasharon, Israel